Clinical Trial Update: A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 study evaluating the combination of LEE011 (ribociclib) and Everolimus in patients with advanced neuroendocrine tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Everolimus (everolimus)
• LEE011 (ribociclib) (ribociclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2024-10-10